Cevostamab Trial Validates FcRH5 as a Multiple Myeloma Target

Findings from the phase 1 GO39775 trial (NCT03275103) showed that cevostamab, a first-in-class FcRH5/CD3 bispecific antibody, was an active agent in heavily pretreated relapsed or refractory multiple myeloma with a manageable safety profile and durable remissions, including after fixed-duration treatment was stopped.

In a conversation with CancerNetwork^®, lead study author Adam D. Cohen, MD, director of Myeloma Immunotherapy and professor of medicine at the Hospital of the University of Pennsylvania, spoke about the key takeaways he hopes others draw from the trial’s results. Of note, he described how the results validate FcRH5 as a target in multiple myeloma therapy.

Transcript:

CancerNetwork: What do you hope others take away from the results of this trial?

I think the key takeaways are, one, it validates FcRH5 as a good target for [multiple] myeloma therapy. This is the first trial to do that, and it is clearly an active agent against a good target. Two, fixed-duration therapy, as we have talked about, is a good concept that this trial is helping to establish, and hopefully, that will become the future. We will be able to tailor the duration of therapy to the response, or to the setting, and not have to keep people on therapy forever.

Quality of life is important, especially in a late-line, maybe incurable setting; drugs that do not cause a lot of nuisance or quality-of-life toxicities can be very important. Lastly, this gets back to the sequencing question: how do we optimally use all of these different T-cell–directed agents, and what is the optimal timing? I think we need more studies and more data, and some of these questions may have to be answered in the real-world setting, so we encourage centers to pool their data. The International Myeloma Working Group has an immunotherapy database where we are trying to capture how all of these agents are being used in the real world, and those kinds of studies can be important for optimizing sequencing going forward.

Reference

Cohen AD, Richter J, Trudel S, et al. FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial. Nat Med. Published online July 22, 2026. doi:10.1038/s41591-026-04522-3